Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
05
03
2023
accepted:
05
07
2023
medline:
18
9
2023
pubmed:
1
9
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and single-cell whole-genome sequencing and copy number variation analysis of 30 patients treated with anti-BCMA and/or anti-GPRC5D CAR T/TCE therapy. In two cases, MM relapse post-TCE/CAR T therapy was driven by BCMA-negative clones harboring focal biallelic deletions at the TNFRSF17 locus at relapse or by selective expansion of pre-existing subclones with biallelic TNFRSF17 loss. In another five cases of relapse, newly detected, nontruncating, missense mutations or in-frame deletions in the extracellular domain of BCMA negated the efficacies of anti-BCMA TCE therapies, despite detectable surface BCMA protein expression. In the present study, we also report four cases of MM relapse with biallelic mutations of GPRC5D after anti-GPRC5D TCE therapy, including two cases with convergent evolution where multiple subclones lost GPRC5D through somatic events. Immunoselection of BCMA- or GPRC5D-negative or mutant clones is an important tumor-intrinsic driver of relapse post-targeted therapies. Mutational events on BCMA confer distinct sensitivities toward different anti-BCMA therapies, underscoring the importance of considering the tumor antigen landscape for optimal design and selection of targeted immunotherapies in MM.
Identifiants
pubmed: 37653344
doi: 10.1038/s41591-023-02491-5
pii: 10.1038/s41591-023-02491-5
pmc: PMC10504087
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Antibodies
0
Membrane Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2295-2306Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s).
Références
Caraccio, C., Krishna, S., Phillips, D. J. & Schürch, C. M. Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions. Front. Immunol. 11, 501 (2020).
doi: 10.3389/fimmu.2020.00501
pubmed: 32391000
pmcid: 7193016
Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985–1005 (2020).
doi: 10.1038/s41375-020-0734-z
pubmed: 32055000
pmcid: 7214244
Truger, M. S. et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 5, 3794–3798 (2021).
doi: 10.1182/bloodadvances.2021004418
pubmed: 34471932
pmcid: 8679680
Tai, Y. T. & Anderson, K. C. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert. Opin. Biol. Ther. 19, 1143–1156 (2019).
doi: 10.1080/14712598.2019.1641196
pubmed: 31277554
pmcid: 6785394
The UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. https://doi.org/10.1093/nar/gkac1052 (2022).
Pillarisetti, K. et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D × CD3 antibody to treat multiple myeloma. Blood 135, 1232–1243 (2020).
doi: 10.1182/blood.2019003342
pubmed: 32040549
pmcid: 7146017
Smith E. L., et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aau7746 (2019).
Usmani, S. Z. et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398, 665–674 (2021).
doi: 10.1016/S0140-6736(21)01338-6
pubmed: 34388396
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
doi: 10.1056/NEJMoa2024850
pubmed: 33626253
Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021).
doi: 10.1016/S0140-6736(21)00933-8
pubmed: 34175021
Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. N. Engl. J. Med. 387, 1196–1206 (2022).
doi: 10.1056/NEJMoa2209900
pubmed: 36170501
pmcid: 10309537
Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232–2244 (2022).
doi: 10.1056/NEJMoa2204591
pubmed: 36507686
Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022).
doi: 10.1056/NEJMoa2203478
pubmed: 35661166
pmcid: 10587778
O’Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151–167 (2019).
doi: 10.1038/s41571-018-0142-8
pubmed: 30523282
Da Vià, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616–619 (2021).
doi: 10.1038/s41591-021-01245-5
pubmed: 33619368
Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021).
doi: 10.1038/s41467-021-21177-5
pubmed: 33558511
pmcid: 7870932
Pillarisetti K. et al. Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof. Patent. Feb;WO 2017/031104 A1. World Intellectual Property Organization https://patents.google.com/patent/WO2017031104A1/en (2017).
Marino, S. F., Olal, D. & Daumke, O. A complex water network contributes to high-affinity binding in an antibody-antigen interface. Data Brief. 6, 394–397 (2016).
doi: 10.1016/j.dib.2015.12.023
pubmed: 26862587
Oden, F. et al. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma. Mol. Oncol. 9, 1348–58 (2015).
doi: 10.1016/j.molonc.2015.03.010
pubmed: 25953704
pmcid: 5528805
Madej, T. et al. MMDB and VAST+: tracking structural similarities between macromolecular complexes. Nucleic Acids Res. 42, D297–D303 (2014).
doi: 10.1093/nar/gkt1208
pubmed: 24319143
Maity, R. et al. A BCL2L1 armoured BCMA targeting CAR T cell to overcome exhaustion and enhance persistence in multiple myeloma. Blood 1381, 327 (2021).
doi: 10.1182/blood-2021-153871
Cunningham, F. et al. Ensembl 2022. Nucleic Acids Res. 50, D988–D995 (2021).
doi: 10.1093/nar/gkab1049
pmcid: 8728283
Laurent, S. A. et al. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun. 6, 7333 (2015).
doi: 10.1038/ncomms8333
pubmed: 26065893
Skerget S. et al. Genomic basis of multiple myeloma subtypes from the MMRF CoMMpass study. Preprint at medRxiv https://doi.org/10.1101/2021.08.02.21261211 (2021).
Samur, M. K. et al. Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors. Blood. 1401, 2106–2107 (2022).
doi: 10.1182/blood-2022-168903
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29 (2021).
doi: 10.1016/j.cell.2021.04.048
pubmed: 34062119
pmcid: 8238499
Raine, K. M. et al. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr. Protoc. Bioinform. 56, 15.9.1–15.9.17 (2016).
doi: 10.1002/cpbi.17
Maura, F. et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun. 10, 3835 (2019).
doi: 10.1038/s41467-019-11680-1
pubmed: 31444325
pmcid: 6707220
Pruitt, K. D. et al. The consensus coding sequence (CCDS) project: identifying a common protein-coding gene set for the human and mouse genomes. Genome Res. 19, 1316–23 (2009).
doi: 10.1101/gr.080531.108
pubmed: 19498102
pmcid: 2704439
Van Der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701–18 (2005).
doi: 10.1002/jcc.20291
pubmed: 16211538
Comeau, S. R., Gatchell, D. W., Vajda, S. & Camacho, C. J. ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics 20, 45–50 (2004).
doi: 10.1093/bioinformatics/btg371
pubmed: 14693807
Ou, J. & Zhu, L. J. trackViewer: a Bioconductor package for interactive and integrative visualization of multi-omics data. Nat. Methods 16, 453–454 (2019).
doi: 10.1038/s41592-019-0430-y
pubmed: 31133757